BIOGNOSYS
15.3.2022 14:02:09 CET | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces T-Rex Dual Solar, the First AMOLED Smartwatch with Dual-Sided Solar Charging22.9.2026 13:00:00 CEST | Press release
Built for adventures beyond the grid, T-Rex Dual Solar combines a bright AMOLED display with dual-sided solar energy recovery designed to extend battery life when access to traditional power is limited. Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Dual Solar, a premium expedition smartwatch built for long-distance and multi-day exploration. Launching on the autumnal equinox — a day defined by the balance of sunlight and darkness — the T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through an innovative glass ceramic back plate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922588618/en/ The Amazfit T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through
Saildrone USVs Receive Danish Flag Registration for European Operations22.9.2026 12:45:00 CEST | Press release
Saildrone today announced that the first four Saildrone Voyager USVs (unmanned surface vehicles) have been registered in Denmark and will operate under the Danish flag, marking the first time Saildrone USVs will operate under a national flag. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922488140/en/ A Saildrone Voyager operates in the Baltic Sea in support of maritime domain awareness missions. The 10-meter USV is one of the first Saildrone platforms registered in Denmark to operate under the Danish flag. The registration establishes a clear flag-state framework for Saildrone USVs operating internationally. Working together, Saildrone and the Danish Maritime Authority developed the regulatory framework necessary to register and operate unmanned surface vehicles under the Danish flag. “We are pleased that Saildrone has chosen Denmark as the flag state for the company’s uncrewed vessels. This underscores that Denmark, as
NIQ Announces Friendly Bid to Acquire The U Group & Co Limited, Expanding Trusted Intelligence for the AI Era22.9.2026 12:45:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia) has launched a conditional off-market offer for all outstanding shares of The U Group & Co Limited (The U Group) as a friendly takeover bid (Offer). The U Group is an Australian-based company specializing in first-party, consumer-consented purchase data collection through its ReceiptJar app, receipt intelligence, and AI-powered data processing capabilities. In connection with the Offer, NIQ Australia has lodged its Bidder's Statement with the Australian Securities and Investments Commission and dispatched the Offer materials to shareholders of The U Group in accordance with applicable Australian regulatory requirements. The Board of The U Group has unanimously recommended that shareholders accept the Offer for the reasons set out in the Target's Statement. The Offer reflects NIQ's commitment to strengthening trust
OKX Sets a New Standard for Account Protection with OKX Shield22.9.2026 12:30:00 CEST | Press release
Up to €500,000 in account protection for customers in EuropeOKX Shield builds on industry-leading safeguards and advanced account security OKX, a leading global cryptocurrency exchange and onchain technology company with more than 150 million customers worldwide, today launched OKX Shield. OKX Shield is an integrated security product suite combining sophisticated safeguards, visible protection status and the potential for customers to be paid back up to €500,000 following a third-party account-takeover. Account takeover fraud is a challenge for all financial businesses to protect customers against, with billions lost every year in Europe. The most recent EBA and ECB data shows €4.2 billion in payment fraud across Europe in 2024, which was up from €3.5 billion in 2023. Customers are being targeted directly, with attempts to compromise their accounts across financial platforms. OKX Shield brings together account-security enhancements with a new protection program, providing up to €500,00
Infobip Predicts 7.3 Billion Black Friday and Cyber Monday Interactions as AI Reshapes the 2026 Shopping Season22.9.2026 12:26:00 CEST | Press release
New research across nine markets finds 63% of consumers have used AI when shopping, while only 19% plan to wait until Black Friday week to begin their holiday shopping Global AI-first cloud communications platform Infobip predicts more than 7.3 billion customer interactions across Black Friday and Cyber Monday 2026, as AI and conversational channels transform how consumers discover products, receive offers and access support. New Infobip research also reveals that 63.2% of consumers have used an AI assistant or chatbot while shopping during the past 12 months. Black Friday is no longer a single shopping event. Infobip’s research shows that the shopping season now begins weeks earlier and continues through the entire customer journey. Nearly six in ten respondents will have started holiday shopping by early November, while only 19% wait until Black Friday week itself. This extended shopping window is creating new pressure for retailers to engage customers earlier, with better timing, mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom